Murine subcutaneous immunotherapy models with beneficial immunological and physiological effects
Asia Pacific Allergy
;
(4): 50-58, 2013.
Article
in English
| WPRIM
| ID: wpr-749928
ABSTRACT
BACKGROUND:
Immunotherapy was introduced 100 years ago and has a unique role in the treatment of allergic diseases in that only immunotherapy can induce long-term immunological tolerance. However, only a few mouse models of immunotherapy have been developed so far.OBJECTIVE:
We tried to establish murine immunotherapy models that have similar findings in human using subcutaneous rush immunotherapy-like schedule.METHODS:
To determine the maximal safe or maximal tolerable dose, injection dose was doubled twice a day from the dose of sensitization. Mice with established asthma using ovalbumin (OVA) were repeatedly injected with OVA from the dose of sensitization subcutaneously twice a day after reaching to the maximal safe or maximal tolerable dose, mice were injected with each dose either 10 times or 24 times.RESULTS:
Short term immunotherapy (10 times) with the maximal safe and tolerable dose of OVA showed decreased IL-5 production, decreased IL-5/INF-γ ratio, and increased IgG2a/IgG1 but there was no significant difference in airway hyperresponsiveness (AHR) or airway inflammation. Prolonged immunotherapy (24 times) with the maximal tolerable dose not only decreased cytokine productions of IL-5 and even INF-γ, but also decreased IgE, IgG1 and even IgG2a production. Remarkably, the prolonged immunotherapy provided a protective effect on AHR.CONCLUSION:
This study suggested immunotherapy models with some beneficial immunological and physiological effects in murine asthma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Ovum
/
Appointments and Schedules
/
Asthma
/
Immunoglobulin E
/
Immunoglobulin G
/
Ovalbumin
/
Interleukin-5
/
Models, Animal
/
Hypersensitivity
/
Immunotherapy
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Asia Pacific Allergy
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS